Log In
BCIQ
Print this Print this
 

MK-3682 (formerly IDX21437)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionUridine nucleotide analog HCV NS5B polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotypes 1, 2 and 3 infection; Treat HCV infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,700.0M

$3,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/05/2014

$3,700.0M

$3,700.0M

0

Get a free BioCentury trial today